Drugs / ZKY001
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06209203 | Aug → Nov 2022 | corneal disorder | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06213727 | Mar → Nov 2022 | corneal disorder | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT07120308 | Sep 2021 → Jan 2023 | corneal disorder | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04228926 | Dec 2020 → Dec 2021 | corneal disorder | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZKY001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06213727 ↗ |
| Route | Other | “ZKY001 eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).” NCT04228926 ↗ |